X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
life sciences & biomedicine (14) 14
science & technology (14) 14
ustekinumab (13) 13
psoriasis (12) 12
interleukin-12 (8) 8
interleukin-12/23 (8) 8
male (8) 8
adult (7) 7
dermatology (7) 7
female (7) 7
middle aged (7) 7
antibodies, monoclonal - therapeutic use (6) 6
crohn disease - drug therapy (5) 5
double-blind method (5) 5
interleukin-12/23 monoclonal antibody (5) 5
interleukin-23 - antagonists & inhibitors (5) 5
antibodies, monoclonal, humanized (4) 4
clinical trials (4) 4
crohn's disease (4) 4
interleukin-12 - antagonists & inhibitors (4) 4
interleukin-23 (4) 4
interleukins (4) 4
review (4) 4
anti-interleukin-12/23 (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
arthritis (3) 3
arthritis, psoriatic - drug therapy (3) 3
cytokines (3) 3
inflammatory bowel disease (3) 3
janus kinase inhibitors (3) 3
monoclonal antibodies (3) 3
pharmacology & pharmacy (3) 3
psoriasis - drug therapy (3) 3
psoriasis - pathology (3) 3
psoriatic arthritis (3) 3
quality of life (3) 3
severity of illness index (3) 3
tumor necrosis factor-alpha - antagonists & inhibitors (3) 3
ustekinumab - therapeutic use (3) 3
animals (2) 2
anti-inflammatory agents, non-steroidal - therapeutic use (2) 2
anti-mucosal vascular addressin cell adhesion molecule-1 agent (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - immunology (2) 2
antibodies, monoclonal - pharmacokinetics (2) 2
asian continental ancestry group (2) 2
biologics (2) 2
clinical, cosmetic and investigational dermatology (2) 2
colitis, ulcerative - drug therapy (2) 2
crohn disease - physiopathology (2) 2
crohn’s disease (2) 2
cross-over studies (2) 2
cytokines - metabolism (2) 2
dermatology life quality index (2) 2
drug therapy (2) 2
gastroenterology & hepatology (2) 2
general & internal medicine (2) 2
health-related quality of life (2) 2
immunology (2) 2
inflammatory bowel diseases (2) 2
injections, subcutaneous (2) 2
interleukin-12 - metabolism (2) 2
interleukin-12/23 inhibitors (2) 2
interleukin-12/23 p40 (2) 2
interleukin-17 inhibitors (2) 2
interleukin-23 - metabolism (2) 2
japan (2) 2
medical colleges (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
pathogenesis (2) 2
psoriasis - therapy (2) 2
treatment outcome (2) 2
tumor necrosis factor-tnf (2) 2
ustekinumab - administration & dosage (2) 2
ustekinumab - pharmacology (2) 2
1506 (1) 1
23 monoclonal antibody (1) 1
adaptive immunity (1) 1
aged (1) 1
analysis (1) 1
anti-inflammatory agents - therapeutic use (1) 1
anti-inflammatory agents, non-steroidal - adverse effects (1) 1
anti-interleukin-12 (1) 1
anti-interleukin-12/-23 p40 (1) 1
anti-interleukin-17 (1) 1
anti-interleukin-23 (1) 1
anti-smad7 antisense oligo nucleotide (1) 1
anti-smad7 antisense oligonucleotide (1) 1
anti-tumour necrosis factor alpha inhibitors (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - chemistry (1) 1
antigens (1) 1
antirheumatic agents - therapeutic use (1) 1
antisense therapy (1) 1
apremilast (1) 1
arthritis, psoriatic - immunology (1) 1
arthritis, psoriatic - therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International journal of clinical pharmacology and therapeutics, ISSN 0946-1965, 12/2010, Volume 48, Issue 12, pp. 830 - 846
Purpose: To characterize the population pharmacokinetics of subcutaneous ustekinumab, a human IgG 1 kappa monoclonal antibody against interleukin-12/23p40, using data from a randomized, double-blind, placebo... 
Ustekinumab | Interleukin-12/23 p40 | Population pharmacokinetics | Monoclonal antibody | Psoriatic arthritis | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Body Weight | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - pharmacokinetics | Male | Antibodies, Monoclonal, Humanized | Models, Biological | Arthritis, Psoriatic - drug therapy | Adult | Female | Aged | Antibodies, Monoclonal - immunology
Journal Article
Clinical, cosmetic and investigational dermatology, ISSN 1178-7015, 2009, Volume 2, pp. 95 - 103
Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting approximately 2% to 3% of Caucasian population. Given the... 
Psoriasis | Interleukin-12/23 monoclonal antibody | Ustekinumab | Pathogenesis
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 11/2016, Volume 10, pp. 3685 - 3698
.... Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation... 
Inflammatory bowel disease | Interleukin-12/23 monoclonal antibody | Ustekinumab | Interleukin-12 | Interleukin-23 | Crohn’s disease | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Ustekinumab - pharmacology | Interleukin-12 - metabolism | Ustekinumab - chemistry | Ustekinumab - therapeutic use | Interleukin-23 - metabolism | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Interleukin-23 - antagonists & inhibitors | Arthritis, Psoriatic - drug therapy | Crohn Disease - drug therapy | Interleukin-12 - antagonists & inhibitors | Crohn Disease - physiopathology | Ustekinumab - administration & dosage | Antibodies, Monoclonal, Humanized - chemistry | Care and treatment | Crohn's disease | Immunotherapy | Patient outcomes | Methods | Interleukin | Immunoglobulin G | Clinical trials | Interleukin 23 | Arthritis | Drug development | Cell surface | Immunity | Immunology | Lymphocytes | Gastroenterology | Remission | Tumor necrosis factor-TNF | Colon | Drug dosages | Medical research | Immune response | Psoriasis | Cytokines | Dendritic cells | Medical treatment | Interleukin 12 | Pharmacology | Inflammation | Adaptive immunity | FDA approval | Crohns disease | Monoclonal antibodies | Ligands | Pharmacokinetics | Index Medicus | inflammatory bowel disease
Journal Article
Dermatology and therapy, ISSN 2193-8210, 12/2012, Volume 2, Issue 1, pp. 1 - 10
Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and... 
Plastic Surgery | Biologic therapies | Psoriasis | Dermatology | Interleukin-12/23 | Phosphodiesterase 4 inhibitors | Quality of Life Research | Internal Medicine | Oral and Maxillofacial Surgery | Interleukin-20/22 | Medicine & Public Health | Janus kinase inhibitors | Interleukin-17 | Psoria
Journal Article
The Korean journal of internal medicine, ISSN 1226-3303, 2018, Volume 33, Issue 1, p. 20
... oligonucleotide, an anti-interleukin-12/23 monoclonal antibody, and a sphingosine-1-phosphate... 
Inflammatory bowel diseases | Janus kinase inhibitors | Anti-SMAD7 antisense oligo nucleotide | Anti-mucosal vascular addressin cell adhesion molecule-1 agent | Anti-interleukin-12/23
Journal Article
Intestinal research, ISSN 2288-1956, 2017, Volume 15, Issue 4, pp. 475 - 486
Background/Aims: Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn's disease (CD) in... 
Ustekinumab | Crohn disease | Interleukin-12/23 | Japan | Original | Interleukin-12
Journal Article